Latest news with #SummitPartners
Yahoo
21 hours ago
- Business
- Yahoo
Klaviyo Announces Launch of Proposed Secondary Offering of Series A Common Stock
BOSTON, August 13, 2025--(BUSINESS WIRE)--Klaviyo, Inc. (the "Company") (NYSE: KVYO), the only CRM built for B2C brands, today announced the commencement of an underwritten public offering (the "offering") of 6,500,000 shares of its Series A common stock, par value $0.001 per share (the "Series A Common Stock"), by entities affiliated with Summit Partners, L.P. (the "Selling Stockholders"). The Selling Stockholders also expect to grant the underwriter a 30-day option to purchase up to an additional 975,000 shares of Series A Common Stock. The Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Barclays is acting as the underwriter for the offering. The underwriter may offer the shares of Series A Common Stock from time to time in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. A registration statement on Form S-3 relating to the shares of Series A Common Stock was filed with the Securities and Exchange Commission (the "SEC") on February 19, 2025 and became effective upon filing. The offering will be made only by means of a prospectus supplement and an accompanying prospectus. A copy of these documents may be obtained, when available, by visiting the SEC's website at or by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone 1-888-603-5847, or by email: barclaysprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Klaviyo Klaviyo (NYSE: KVYO) is the only CRM built for B2C brands. Powered by its built-in data platform and AI insights, Klaviyo combines marketing automation, analytics, and customer service into one unified solution, making it easy for businesses to know their customers and grow faster. Klaviyo (CLAY-vee-oh) helps relationship-driven brands like Mattel, Glossier, CorePower Yoga, Daily Harvest and 176,000+ others deliver 1:1 experiences at scale, improve efficiency, and drive revenue. Forward-Looking Statements This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including among other things, statements concerning the completion of the offering. These forward-looking statements include, but are not limited to, plans, intentions, expectations, strategies and prospects and other statements contained in this press release that are not historical facts and statements identified by words such as "will," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities, and other risks set forth under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the preliminary prospectus supplement and the accompanying prospectus related to the offering and in subsequent filings made by the Company with the SEC. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. View source version on Contacts Source: Klaviyo, IR Press Amy Hufftpress@ Investor Relations Andrew Zilliir@
Yahoo
26-07-2025
- Business
- Yahoo
Unilever's (UL) Resilient Business Model Underpins Its Dividend Reliability
Unilever PLC (NYSE:UL) is included among the Top 10 Safest Dividend Stocks in the UK. A supermarket shelf overflowing with a variety of fast-moving consumer goods. The U.K.-based giant Unilever PLC (NYSE:UL) holds a vast portfolio of consumer staples and everyday household brands, spanning everything from cleaning supplies and personal care products to food items. In June, the company reached a deal to purchase the men's grooming company Dr. Squatch from private equity firm Summit Partners in a transaction valued at $1.5 billion, as per a Financial Times report. Dr. Squatch has built a strong reputation for offering high-quality, natural personal care items, particularly appealing to millennial and Gen Z male consumers. The company is reportedly on course to exceed $400 million in annual revenue. In the first quarter, Unilever PLC (NYSE:UL) achieved underlying sales growth of 3%, demonstrating the strength of its increasingly premium and innovation-driven portfolio in developed markets. It has implemented strategies in certain emerging markets to accelerate growth in the remainder of the year. Despite ongoing global economic uncertainties, the company remains confident in meeting its full-year targets due to the quality of its innovation program, substantial brand investments, and enhanced competitiveness. Unilever PLC (NYSE:UL) also grabs investors' attention due to its strong dividend policy. The company currently offers a quarterly dividend of $0.5151 per share and has a dividend yield of 3.21%, as of July 25. While we acknowledge the potential of UL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Business
- Yahoo
Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
LONDON & BOSTON & STRASBOURG, France, July 14, 2025--(BUSINESS WIRE)--Summit Partners today announced a growth investment in Dreampath Diagnostics, a leading healthcare technology company focused on digitizing workflows in anatomical pathology laboratories. The investment will support the company's plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio. Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers. "Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world." Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples. Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today. "Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale." "We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally." Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors. Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York. Financial terms of the transaction were not disclosed. About Dreampath Diagnostics Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit About Summit Partners Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit or follow on LinkedIn. View source version on Contacts Media Contact:Susan Barrsbarr@
Yahoo
14-07-2025
- Business
- Yahoo
Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
LONDON & BOSTON & STRASBOURG, France, July 14, 2025--(BUSINESS WIRE)--Summit Partners today announced a growth investment in Dreampath Diagnostics, a leading healthcare technology company focused on digitizing workflows in anatomical pathology laboratories. The investment will support the company's plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio. Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers. "Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world." Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples. Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today. "Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale." "We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally." Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors. Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York. Financial terms of the transaction were not disclosed. About Dreampath Diagnostics Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit About Summit Partners Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit or follow on LinkedIn. View source version on Contacts Media Contact:Susan Barrsbarr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Unilever Expands Personal Care Portfolio With Acquisition of Dr. Squatch
Unilever's personal care division is continuing its acquisition spree. After snapping up British deodorant brand Wild, it has signed an agreement to acquire men's personal care and grooming brand Dr. Squatch from private equity firm Summit Partners. More from WWD Michael Bosstick's Dear Media Acquires Fitness Platform Obé Fitness The 3 Best Self-Tanners for Beginners to Get a Faux Glow Like a Pro, Tested by Editors The Best Bronzing Drops That Deliver an Instant Glow and Improve Your Natural Complexion, Tested by Editors The terms of the deal were not disclosed, but the brand's sales are understood to be in excess of $400 million. Of the deal, Fabian Garcia, president of Unilever Personal Care, said: 'Dr. Squatch has built a solid foundation and loyal following with highly desirable products and clever digital engagement strategies. Building on its success in the U.S., we are excited to scale the brand internationally and complement our offering in the fast-growing men's personal care segment.' Josh Friedman, chief executive officer of Dr. Squatch, added: 'Our mission at Dr. Squatch is to inspire and educate men to be happier and healthier, and we're excited about our ability to amplify our brand and mission in this next chapter with Unilever. We're just getting started at Dr. Squatch, and we are thrilled about the opportunity to advance the brand's scale, reach new heights internationally, and entertain and positively connect with more consumers seeking high-quality, natural products around the world.' The brand was founded in 2013 in California by Jack Haldrup with handmade soaps, before expanding into deodorant, hair care, colognes and more. In 2019, it raised a seed round and in 2022, Summit Partners took a majority stake in the business. According to various reports, it has been exploring sale options for around a year, hoping for a $2 billion valuation. Most recently, it has partnered with celebrities including Sydney Sweeney and Nick Cannon and debuted a Super Bowl ad in 2024. It is distributed through digital commerce, retail and direct-to-consumer channels, primarily in North America and Europe. In April, Unilever acquired Wild for a reported 230 million pounds. Wild was founded in 2020, with deodorant in reusable aluminum cases and biodegradable refills. It subsequently expanded its range to include body wash, hand wash and lip balms, all featuring refillable packaging. But as it snaps up new brands, Unilever has also been shuttering or divesting others. In May, it closed Ren Clean Skincare, blaming a combination of 'internal factors, compounded by market challenges. And last summer, Yellow Wood Partners completed the acquisition of Elida Beauty brands from Unilever, which included Q-tips, Caress, Ponds and St. Ives. CEO Fernando Fernandez has also outlined plans to offload underperforming food brands. Best of WWD Sesame Oil Skin Care: The Secret to Hydrated Skin or a Recipe for Clogged Pores? How Grooming Is Introducing Men to Self-care and Redefining Masculinity Clean Beauty Brand Ignae Makes Big U.S. Push With a New Look Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
